Objectives: The contribution of integrons and efflux pumps to multidrug resistance in Stenotrophomonas maltophilia was evaluated.
Introduction
The incidence of Stenotrophomonas maltophilia as a cause of nosocomial bacteraemias caused by Gram-negative organisms is now second only to Pseudomonas aeruginosa. Isolation of S. maltophilia is reported with increasing frequency, 1 and intrinsic resistance and the ready selection of high-level multidrug resistance are a major problem in clinical isolates. 2 The mechanisms of antibacterial drug resistance in clinical isolates of S. maltophilia have not been studied in detail. However, resistance is partly attributable to limited outer membrane permeability and active antibiotic efflux; 3 two Sme efflux systems, SmeABC and SmeDEF, have been identified. 4, 5 In many other Gram-negative bacteria, integrons carrying antibiotic resistance genes have been identified on mobile elements, such as transposons and plasmids, and these facilitate transfer of antibiotic resistance genes between different species. 6 In the present study, the distribution of class 1 and 2 integrons was examined in a collection of clinical isolates of S. maltophilia. The levels of expression of the SmeABC and SmeDEF pumps were also analysed and were correlated with the antibiotic susceptibilities of the isolates.
Material and methods
Ninety-three S. maltophilia isolates were collected at the Kaohsiung Medical University Hospital during January-December 2002. Isolates were obtained from sputum (n = 54), wounds (n = 14), central venous catheter (n = 8), urine (n = 5), bile (n = 4), blood (n = 4), throat swabs (n = 2), cerebrospinal fluid (n = 1) and eye (n = 1). Identification was performed with API 20E (bioMérieux, La Balme, France) or the Vitek automated system (bioMérieux, Vitek, Hazelwood, MO, USA). Random amplified polymorphic DNA (RAPD) markers (Operon Technologies, Inc., Alameda, CA, USA) were used to determine the degree of relatedness between the isolates. S. maltophilia ATCC 13637 was used as a wild-type control strain.
Antimicrobial susceptibilities were determined by the agar dilution methods described by the NCCLS. 7 The template DNA for PCR was prepared as described by Bass et al. 8 Integrons were detected with integrase-specific primers for intI 1 (F: 5′-CCTCCCGCACGATGATC-3′, R: 5′-TCCACGCATCGTCAG-GC-3′) or intI 2 (F: 5′-ATGTCTAACAGTCCATTTTTAAATT-3′, R: 5′-GTAGCAAACGAGTGACGAAATG-3′). Gene cassettes within integrons were amplified with primers specific for the integron 5′ conserved segment (5′-GGCATCCAAGCAGCAAG-3′) and 3′ conserved Plasmid DNA was extracted by the method of Kado & Liu. 9 Hybridization was performed with a digoxigenin-labelled probe specific for the integrase gene intI 1.
In real-time PCR, the sequences of the primers for the target genes were as follows: smeB (F: 5′-GGGCCGGAAAGCTACGA-3′, R: 5′-AGC-GAAATGGTCACGAATGG-3′); and smeF (F:5′-CCAACGCGGAT-CGTGATATC-3′, R: 5′-TGCTCATCCAGGCTGACATTC-3′). The primer sequences for the endogenous control gene were: rDNA (F: 5′-GAC-CTTGCGCGATTGAATG-3′, R: 5′-CGGATCGTCGCCTTGGT-3′).
Total RNA was isolated using the High Pure RNA Isolation Kit (Roche, Mannheim, Germany) and reverse transcribed using oligo (dT) 15 and avian myeloblastosis virus reverse transcriptase (Promega, Madison, USA) in a 20 µL reaction. Then, real-time PCR reactions were performed on an ABI Prism 7900 thermal cycler (Applied Biosystems, Foster, CA, USA). Amplification mixtures (50 µL) for smeB, smeF and rDNA quantification contained template cDNA, 2×SYBR Green I Master Mix (Applied Biosystems) and primers. PCR was accomplished after a 10 min activation and denaturation step at 95°C, followed by 40 cycles of 15 s at 95°C, and 1 min at 59°C (for smeB) or 58°C (for smeF and rDNA) for annealing and extension. The parameter Ct was defined as the threshold cycle number at which the fluorescence generated by the binding of SYBR Green I dye to double-stranded DNA began to increase exponentially.
Clinical S. maltophilia isolate 14109 was chosen to construct the standard curve of smeABC, smeDEF and rDNA. S. maltophilia ATCC 13637 was used as calibrator to normalize the relative expression level of smeB and smeF genes in clinical isolates. Final results, expressed as n-fold differences in expression of smeABC or smeDEF genes, were determined as follows:
Values of n < 1 were considered to indicate overexpression of the Sme efflux system.
Statistical analysis
t-Tests (two-tailed) and ANOVA tests were used to determine the correlation between overexpression of the Sme efflux pumps and drug resistance in clinical isolates of S. maltophilia.
Results
Of four random primers used, two (OPAB09 and OPAB03) gave well-defined banding patterns. The RAPD patterns of the 93 isolates were not completely identical. Therefore, although the isolates were from the same hospital, strain diversity was observed. The results of susceptibility testing showed that most of the S. maltophilia isolates were resistant to gentamicin (92%), cefoperazone (66%), imipenem (100%), meropenem (100%), carbenicillin (100%) and tetracycline (100%). Among the agents tested, ticarcillin-clavulanate was the most active against S. maltophilia (87% susceptible). Although trimethoprim-sulfamethoxazole is considered the drug of choice for S. maltophilia infections, 25% of isolates were resistant.
Twenty (22%) isolates carried detectable class 1 integrons; class 2 integrons were not found. Four different resistance cassette arrays were identified: aacA4 only (resistance to aminoglycosides, including amikacin) in five isolates; dfrIIa only (trimethoprim) in seven isolates; and the small multidrug resistance gene, smr, alone in four isolates and with aacA4 in two others. Two isolates contained 'empty' integrons that lacked resistance cassettes. The six smrpositive isolates showed an ∼four-fold increase in MICs of ciprofloxacin in comparison with isolates that did not carry this gene. Ten (11%) isolates possessed plasmid DNA, but Southern hybridization revealed that only one isolate carried a plasmid-mediated integron; this harboured an aacA4 gene cassette.
Real-time PCR methods were performed to assess and quantify expression of the Sme efflux systems among S. maltophilia. Our data indicated that smeF was overexpressed by 29 (31%) of the clinical isolates analysed. MICs of meropenem were significantly higher for isolates in which smeF was detectable by real-time PCR than for isolates in which it was not detectable ( Table 1 ). The SmeABC efflux system was not expressed in wild-type S. maltophilia ATCC 13637. Fifty-five (59%) clinical isolates overexpressed smeABC and showed significantly increased resistance to ciprofloxacin (Table 1) . In Table 2 , we used an ANOVA method to compare the resistance of isolates in three categories; those containing both smeB and smeF, those containing only one of these genes and those with neither gene. The test would regard as significant only those values where P < 0.01. However, none of the results reached this level of significance. 
Discussion
The mechanisms of antibacterial drug resistance in S. maltophilia have not been studied in detail previously, but many of the acquired mechanisms found in P. aeruginosa and other Gram-negative bacteria are likely to be present. Previous reports have detected class 1 integrons in many (40%-60%) Gram-negative clinical isolates, with plasmids or transposons contributing to their dissemination. 6 However, in this study, only 22% (20/93) of S. maltophilia clinical isolates had class 1 integrons, and only one of these was located on a plasmid. The results are consistent with our previous report analysing plasmid content of P. aeruginosa, where 15.2% of isolates carried plasmids, but only 13.3% of plasmid-carrying strains contained R plasmids. 10 These results suggest that integrons and plasmids might not play important roles in the multidrug resistance of S. maltophilia. Interestingly, an smr gene was detected on integrons in six isolates. Proteins of the SMR family have been characterized in Escherichia coli (EmrE Eco ) and P. aeruginosa (EmrE Pae ); they contribute to resistance to multiple toxic compounds and antimicrobial agents, especially aminoglycosides. 11 The role and contribution of smr to the drug resistance of S. maltophilia merits further study.
Using antibiotics as the selective agent, Zhang et al. 5 reported the isolation of a number of multidrug-resistant strains of S. maltophilia resistant to fluoroquinolones, tetracycline and chloramphenicol. The multidrug-resistant phenotypes of the mutants were attributed to multidrug efflux systems. Two efflux systems, SmeABC and SmeDEF, have been identified in S. maltophilia. 4, 5 Alonso & Martinez 2 analysed the expression of the SmeF protein by western blotting with an anti-SmeF antibody and showed that 47% of the strains examined overproduced this protein. Furthermore, the MICs of tetracycline, chloramphenicol, erythromycin and the quinolones were higher for strains in which expression of SmeF was detectable by western blotting. Similarly, Li & Poole 4 used deletion experiments to indicate that SmeABC also contributes to antimicrobial resistance. In addition, overexpression of smeABC genes in a constructed multidrug resistant strain induced resistance to several antimicrobials, including aminoglycosides, β-lactams and fluoroquinolones. 4 In the present study, real-time PCR was used to quantify and compare the expression of SmeABC and SmeDEF efflux pumps in clinical isolates. We showed that the SmeABC and SmeDEF efflux pumps play a role in resistance of S. maltophilia to ciprofloxacin and meropenem, respectively.
In summary, the driving force behind the accelerated evolution of multidrug resistance in clinical isolates of S. maltophilia remains unclear, but could in part be the use of antibiotics in clinical settings and the presence of efflux pump systems. Increasingly, combinations of antimicrobial agents may be needed for the therapy of resistant S. maltophilia infections. In addition, effective antibiotic therapy of S. maltophilia infections may require the development of derivatives that are poor substrates for the efflux pumps and of pump inhibitors to restore susceptibility to available antimicrobial agents. 12 
